Multi-CAR T Cell Therapy Targeting CD7-positive Malignancies

NCT04033302 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

UNKNOWN

Status

30

Enrollment

OTHER

Sponsor class

Conditions

T-cell Acute Lymphoblastic Leukemia
T-cell Acute Lymphoblastic Lymphoma
Acute Myeloid Leukemia
NK Cell Lymphoma

Interventions

BIOLOGICAL: CD7-specific CAR gene-engineered T cells

Sponsor

Shenzhen Geno-Immune Medical Institute